Mark S. Rubin

Molecular Gene Expression Profiling to Predict the Tissue of Origin and Direct Site-Specific Therapy in Patients With Carcinoma of Unknown Primary Site: A Prospective Trial of the Sarah Cannon Research Institute

John D. Hainsworth, Mark S. Rubin, David R. Spigel et al. · Journal of Clinical Oncology · 2012 · 367 citations · Full text

Phase II Clinical Trial of Paclitaxel Loaded Polymeric Micelle in Patients with Advanced Pancreatic Cancer

Muhammad Wasif Saif, Nikolai A. Podoltsev, Mark S. Rubin et al. · Cancer Investigation · 2009 · 88 citations

Bevacizumab and everolimus in the treatment of patients with metastatic melanoma

John D. Hainsworth, Jeffrey R. Infante, David R. Spigel et al. · Cancer · 2010 · 76 citations

Pazopanib as Second-Line Treatment After Sunitinib or Bevacizumab in Patients With Advanced Renal Cell Carcinoma: A Sarah Cannon Oncology Research Consortium Phase II Trial

John D. Hainsworth, Mark S. Rubin, Edward Arrowsmith et al. · Clinical Genitourinary Cancer · 2013 · 48 citations

Second-line Treatment, Urology, Genitourinary Cancer +4

Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer

David R. Spigel, F. Anthony Greco, Mark S. Rubin et al. · Lung Cancer · 2012 · 39 citations

Medicine, Pharmacology, Phase Ii Study +8